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Abstract 
Cryptococcosis has been one of the most common opportunistic infections and causes of mortality among HIV-
infected patients, especially in resource-limited countries. Cryptococcal meningitis is the most common form of 
cryptococcosis. Laboratory diagnosis of cryptococcosis includes direct microscopic examination, isolation of Cryptococ-
cus from a clinical specimen, and detection of cryptococcal antigen. Without appropriate treatment, cryptococcosis is 
fatal. Early diagnosis and treatment is the key to treatment success. Treatment of cryptococcosis consists of three main 
aspects: antifungal therapy, intracranial pressure management for cryptococcal meningitis, and restoration of immune 
function with antiretroviral therapy (ART). Optimal integration of these three aspects is crucial to achieving successful 
treatment and reducing the mortality. Antifungal therapy consists of three phases: induction, consolidation, and main-
tenance. A combination of two drugs, i.e. amphotericin B plus flucytosine or fluconazole, is preferred in the induction 
phase. Fluconazole monotherapy is recommended during consolidation and maintenance phases. In cryptococcal 
meningitis, intracranial pressure rises along with CSF fungal burden and is associated with morbidity and mortality. 
Aggressive control of intracranial pressure should be done. Management options include therapeutic lumbar punc-
ture, lumbar drain insertion, ventriculostomy, or ventriculoperitoneal shunt. Medical treatment such as corticosteroids, 
mannitol, and acetazolamide are ineffective and should not be used. ART has proven to have a great impact on survival 
rates among HIV-infected patients with cryptococcosis. The time to start ART in HIV-infected patients with cryptococ-
cosis has to be deferred until 5 weeks after the start of antifungal therapy. In general, any effective ART regimen is 
acceptable. Potential drug interactions between antiretroviral agents and amphotericin B, flucytosine, and fluconazole 
are minimal. Of most potential clinical relevance is the concomitant use of fluconazole and nevirapine. Concomitant 
use of these two drugs should be cautious, and patients should be monitored closely for nevirapine-associated adverse 
events, including hepatotoxicity. Overlapping toxicities of antifungal and antiretroviral drugs and immune reconstitu-
tion inflammatory syndrome are not uncommon. Early recognition and appropriate management of these conse-
quences can reinforce the successful integrated therapy in HIV-infected patients with cryptococcosis.
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Background
Cryptococcosis is an important opportunistic infection 
among HIV-infected patients particularly in sub-Saharan 
Africa and in South and Southeast Asia. It is estimated 
that more than 600,000 deaths each year globally are from 
cryptococcosis [1]. The most common clinical presentation 
is cryptococcal meningitis. Pulmonary and other presen-
tations are less common, and disseminated infection may 
occur [2]. Although the widespread availability of antiret-
roviral therapy (ART) has substantially reduced crypto-
coccosis  prevalence worldwide, it is still a major problem 
in developing countries. Without appropriate treatment, 
cryptococcosis is fatal. Early diagnosis and treatment is 
the key to treatment success. Treatment of cryptococcosis 
consists of three main aspects: antifungal therapy, intrac-
ranial pressure management for cryptococcal meningitis, 
and restoration of immune function with ART. Optimal 
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integration of these three aspects is crucial to achieving 
successful treatment and reducing the mortality.
ART has proven to have a great impact on survival 
rates among HIV-infected patients with cryptococco-
sis [3, 4]. The relapse rate of cryptococcal meningitis 
after antifungal therapy is also substantially reduced in 
patients receiving ART [3]. However, the time to start 
ART in HIV-infected patients with cryptococcosis has to 
be carefully considered. A randomized trial has recently 
demonstrated that deferring ART for a specific dura-
tion after the start of antifungal therapy improved sur-
vival rates among patients with cryptococcal meningitis, 
as compared with immediate initiation of ART [5]. This 
improved survival associated with deferring ART was 
observed in patients with advanced HIV infection. An 
integrated therapy of both cryptococcosis and HIV based 
on the current evidence of studies from both diseases 
can yield better survival. This article focuses on the inte-
grated therapy for HIV-infected patients with cryptococ-
cosis and details regarding diagnosis and treatment of 
cryptococcosis, initiation of ART, management of drug–
drug interaction, overlapping toxicities of antifungal and 
antiretroviral drugs, as well as cryptococcal immune 
reconstitution inflammatory syndrome (IRIS).
Clinical manifestations of cryptococcosis in HIV‑infected 
patients
Infection by Cryptococcus is believed to occur mainly 
after inhalation of desiccated yeast cells or basidiospores 
into the alveoli. Other proposed portals of entry include 
gastrointestinal tract, direct inoculation from trauma, 
and transplantation of an infected organ [6–8]. In HIV-
infected patients, dissemination may follow. Alter-
natively, Cryptococcus may initially establish a latent 
infection within thoracic lymph nodes or a pulmonary 
granuloma of a healthy host. These dormant viable yeast 
cells reactivate when the host becomes subsequently 
immunosuppressed. Cryptococcus can infect nearly any 
organ, but the most common are the central nervous sys-
tem (CNS) and the lungs. Wide ranges of clinical mani-
festations and severity have been reported, depending 
on involved organs, patient’s immune status, and species 
or strains of the yeast. HIV-infected patients with cryp-
tococcosis frequently present with disseminated disease 
[9].
Cryptococcal meningitis is the most common form 
of CNS cryptococcosis. Symptoms and signs include 
headache, fever, cranial neuropathy, alteration of con-
sciousness, lethargy, memory loss, and meningeal irri-
tation signs [2, 9]. These signs and symptoms typically 
have a subacute onset, although acute and chronic onset 
can also be observed. Classic signs of meningeal irrita-
tion can present in a minority of patients [9]. Increased 
intracranial pressure often complicates cryptococcal 
meningitis and contributes significantly to the morbidity 
and mortality [10–12]. Patients with cryptococcoma usu-
ally have focal neurological deficits, blindness, seizures, 
as well as signs of increased intracranial pressure [13, 14]. 
Other reported neurological complications include cere-
bral infarction from cerebral vasculitis, and venous sinus 
thrombosis [15, 16].
Pulmonary cryptococcosis has clinical manifestations 
varying from asymptomatic colonization to acute res-
piratory distress syndrome (ARDS). Common signs and 
symptoms in HIV-infected patients are cough, dyspnea, 
pleuritic chest pain, and constitutional symptoms, such 
as fever, malaise, and weight loss [17–21]. Some patients 
may also have hemoptysis and hypoxemia. In HIV-
infected patients, pulmonary cryptococcosis is more 
severe and has a more acute onset than that in other 
hosts. There is a higher risk of progression, with ARDS 
occasionally occurring [18]. Furthermore, pulmonary 
cryptococcosis in HIV-infected patients is usually a clini-
cal manifestation of disseminated infection.
Cutaneous cryptococcosis is characterized by various 
types of skin lesions, including papules, plaques, purpura, 
nodules, ulcers, cellulitis, abscesses, and sinus tracts [22]. 
In AIDS patients, it commonly presents as multiple pain-
less papules with central ulceration, which resembles the 
lesions caused by Molluscum contagiosum, Histoplasma 
capsulatum, Talaromyces marneffei, and Coccidioides 
immitis [22]. Similar to pulmonary cryptococcosis, skin 
lesions are often parts of disseminated disease.
Ocular manifestations of cryptococcosis are occasion-
ally observed. Photophobia, diplopia, papilledema, ocu-
lar palsy, and temporary or permanent visual loss have 
been reported [23–25]. These signs and symptoms are 
due to inflammation from direct invasion of the yeast 
or increased intracranial pressure. Visual loss with a 
rapid onset is usually a result of the former process, 
while a delayed onset is a result of the latter process [25]. 
Although recovery of vision loss related to cryptococ-
cal meningitis is not predictable, dramatic improvement 
with corticosteroids has been reported in patients with 
vision loss from immune reconstitution inflammatory 
syndrome (IRIS) [25].
Cryptococcal lymphadenitis is in the differential diag-
nosis list of HIV-infected patients presenting with lym-
phadenopathy. Cervical lymph nodes are typically the 
most involved. Cryptococcosis of several other sites has 
been reported in the literature. These sites include genital 
and urinary tracts, thyroid, adrenal gland, head and neck, 
breasts, bone and joints, muscles, endocarditis, myocar-
ditis, pericarditis, vascular graft infection, mycotic aneu-
rysm, gastrointestinal nodules or ulcers, hepatitis, and 
peritonitis [26–32].
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Diagnosis of cryptococcosis in HIV‑infected patients
Laboratory diagnosis of cryptococcosis includes direct 
microscopic examination, isolation of Cryptococcus from 
a clinical specimen, and detection of cryptococcal anti-
gen. Cryptococcus in clinical specimens appears as encap-
sulated spherical or oval yeasts without pseudohyphae or 
hyphae. The size of the yeast ranges from 5 to 10 µm. In 
tissues, the yeast usually shows a large capsule. Occasional 
narrow-based buddings may be seen [33]. A number of 
techniques can be employed to visualize the yeast. India 
ink staining shows a clear halo of a capsule around the 
yeast within a black background. India ink staining is usu-
ally applied to cerebrospinal fluid (CSF) and is not suitable 
for other specimens, e.g. urine, sputum, or bronchoalveo-
lar lavage. In HIV-infected patients, the sensitivity of this 
test is over 80%. Centrifugation of CSF may improve the 
sensitivity of the test [33]. Experience is required to dis-
tinguish leukocytes and artefacts from the yeast.
Histopathological examination of biopsies and cytolo-
gies can be applied to various tissues, biological fluids, 
bronchoalveolar lavage, and fine-needle aspirations. 
Hematoxylin and eosin staining usually reveals eosino-
philic or lightly basophilic yeasts with surrounding clear 
halos of the capsules [33]. Tissue reaction varies from 
minimal inflammation in highly immunosuppressed 
host, to a spectrum of granulomatous reactions and 
fibrosis [33]. A number of special stains may be employed 
to better visualize Cryptococcus. Mucicarmine and Alcian 
blue stain the fungal capsule. Gomori methenamine sil-
ver, periodic acid-Schiff, and calcofluor white stain the 
fungal cell wall. The yeast is also positive for Fontana-
Masson staining, since it produces melanin. This feature 
can be used to differentiate Cryptococcus from Candida 
and Histoplasma [33]. Gram stain reveals poorly stained 
gram-positive yeasts, but is not recommended for Cryp-
tococcus identification.
Cryptococcus can be cultured from most sites in stand-
ard fungal media in the absence of cycloheximide. It can 
also grow in bacterial media. Colonies appear on solid 
media as white-to-cream opaque mucoid colonies usu-
ally within 3 days. Delayed growth up to 4 weeks may be 
observed if patients have already received antifungal ther-
apy. Identification of species can be done by biochemical 
methods, molecular methods, or matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry [34]. Sensitivities of CSF and blood cul-
tures in HIV-infected patients with cryptococcal menin-
gitis are approximately 90 and 50–70%, respectively [35]. 
Antifungal susceptibility testing is not routinely recom-
mended for initial management of cryptococcosis, but 
may be considered in relapse and persistent disease [2, 9].
Detection of cryptococcal antigen, which is a compo-
nent of polysaccharide capsule of the yeast, is a highly 
sensitive and specific test. Most clinical specimens are 
CSF and serum. Whole blood and plasma have recently 
been shown to have comparable sensitivity and specific-
ity [36]. Urine cryptococcal antigen testing has also been 
proposed as a non-invasive diagnostic test, albeit lower 
levels of antigen were detected as compared with those 
in the serum [36]. Further studies are warranted regard-
ing the performance of cryptococcal antigen testing in 
specimens other than CSF and blood. Currently, avail-
able detection methods comprise of latex-agglutination, 
enzyme immunoassay, and lateral flow assay. All of them 
showed very high sensitivity and specificity for CSF and 
serum testing [37]. False negative results may be due to 
low fungal burden, poorly encapsulated strains, and if 
latex-agglutination or lateral flow assay is used, prozone/
hook effect [35, 38, 39]. Dilution of samples before test-
ing should be performed in case of suspected prozone or 
hook effect. False positive results of latex agglutination 
test have been rarely reported in infections caused by 
Trichosporon asahii, Stomatococcus mucilaginosus, Kleb-
siella spp., and Capnocytophaga canimorsus and agar 
syneresis fluid [40–43]. Titers of false positive results are 
usually below 1:8. Cryptococcal antigen testing possesses 
not only diagnostic value, but also prognostic value. High 
cryptococcal antigen titers in CSF and serum have shown 
to be associated with poor outcomes, including death, 
relapse, treatment failure and IRIS [44–51]. However, the 
test is not recommended for monitoring after treatment 
(see below).
For HIV-infected patients suspected of having crypto-
coccal meningitis/meningoencephalitis, a lumbar punc-
ture should be performed. Besides the CSF examination, 
this procedure serves to reduce the usually increased 
intracranial pressure. Brain imaging should be sent 
before the procedure in patients who have focal neuro-
logical deficits or impaired consciousness. Analysis of the 
CSF generally reveals normal to mild pleocytosis, with 
a mononuclear predominance, mildly elevated protein 
levels, and low-to normal glucose levels [52–54]. Nor-
mal CSF white blood cell (WBC) counts, protein levels 
and glucose levels can be occasionally observed. A bed-
side procedure of India ink staining is simple and help-
ful. However, given the sensitivity of India ink tests, CSF 
cryptococcal antigen should also be performed regard-
less of the India ink staining results. Testing for serum 
cryptococcal antigen should be considered as well. Posi-
tive cryptococcal antigen testing in the CSF provides a 
strong support for the diagnosis of cryptococcal men-
ingitis/meningoencephalitis, and treatment should be 
administered. CSF culture for fungus should be sent. 
Notably, yields of CSF fungal cultures were shown to be 
higher if a greater amount of CSF was used [55]. A con-
siderable proportion of brain imaging of HIV-infected 
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patients with cryptococcal meningitis/meningoencepha-
litis may be normal or non-specific [56–59]. Indeed, signs 
of meningeal inflammation are usually absent in HIV-
infected patients with cryptococcal meningitis.
In pulmonary cryptococcosis, chest imaging findings 
are various and non-specific. Local or diffuse infiltration, 
nodules, hilar lymphadenopathy, cavitation, and pleural 
effusion have been described [17, 60–62]. Occasionally, 
the findings of diffuse infiltrates may be confused with 
those of Pneumocystis jiroveci pneumonia [60]. Given the 
non-specific nature of imaging, microbiological diagno-
sis is usually required to establish the diagnosis. There 
are several agents of pulmonary opportunistic infection 
in HIV-infected patients, e.g. Nocardia spp., Mycobacte-
rium spp., Pneumocystis jiroveci, and cytomegalovirus. 
Consequently, in addition to sputum, bronchoalveolar 
lavage with or without lung biopsy may be required. In 
HIV-infected patients, pulmonary cryptococcosis may 
progress to, or be a clinical manifestation of dissemi-
nated disease. In fact, those with pulmonary cryptococ-
cosis often already have CNS involvement at diagnosis. 
Serum cryptococcal antigen, blood culture, and lumbar 
puncture with CSF examination should be performed [2]. 
Cryptococcus involvement of other organs, e.g. skin, and 
lymph nodes, usually need histopathological examina-
tion. Investigation for systemic involvement should also 
be considered.
HIV-infected patients with CD4 counts  <100  cells/
µL, especially those not taking ART, are at risk of cryp-
tococcosis. Serum cryptococcal antigen can be detected 
before the onset of symptoms. Screening of such patients 
and preemptive treatment of those whose test is positive 
was shown to improve outcomes and was cost-effective 
[63–65].
Integrated therapy of HIV and cryptococcosis: general 
concept
Without appropriate treatment, cryptococcosis in HIV-
infected patients has a very high mortality rate [66, 67]. 
The two diseases, cryptococcosis and HIV, must be man-
aged simultaneously. Overall mortality in HIV-infected 
patients is high during the first few months of treatment 
[66, 68]. Causes of mortality are cryptococcosis-related, 
other life-threatening opportunistic infections, and/or 
cryptococcal IRIS. Managing the two diseases more effec-
tively during this critical period is essential to improve 
the patients’ survival and quality of life. Although both 
cryptococcosis and tuberculosis occur in HIV-infected 
patients with advanced HIV disease, integrated therapies 
for each disease and HIV are different [69]. The time to 
start ART in HIV-infected patients with cryptococcosis 
has to be carefully considered. A randomized trial has 
recently demonstrated that deferring ART until 5 weeks 
after the start of antifungal therapy improved survival 
rates among patients with cryptococcal meningitis, as 
compared with initiating ART at 1–2  weeks [5]. There-
fore, optimally integrated therapy of HIV and cryptococ-
cosis is the key to improving survival. There are three 
main aspects of integrated therapy for HIV and crypto-
coccosis: (1) antifungal therapy, (2) intracranial pressure 
management for cryptococcal meningitis, and (3) ART to 
restore immune function.
Integration of treatment for both cryptococcosis and 
HIV using a single facility, a single health care provider, 
and delivering care for both diseases is a successful model 
[3, 4, 70]. The advantages include providing optimal tim-
ing for initiation of ART in HIV-infected patients with 
cryptococcosis, holistic evaluation of the patients, and 
practical management when patients encounter drug–
drug interaction or adverse drug effects. In addition, this 
model in resource-limited settings is also more feasible 
to set up, maintain, and train the healthcare providers. 
Interventions for improving adherence and social sup-
port can also better reinforce this approach.
Treatment of cryptococcosis in HIV‑infected patients
Antifungal therapy
Cryptococcus is susceptible to polyenes, flucytosine, and 
azoles. Among these drugs, azoles exhibit the least fun-
gicidal activity. Antifungal treatment for cryptococcosis 
varies according to the disease extent, severity, as well 
as host immune status. Although there are some clinical 
distinctions between cryptococcosis due to C. neofor-
mans and C. gattii, recommended treatment regimens 
for both species are currently identical. Some experts 
suggest that a longer duration of induction and consoli-
dation therapy should be used in C. gattii infection [71, 
72]. Fluconazole monotherapy is recommended for mild-
to-moderate pulmonary disease. In contrast, treatment 
of disseminated disease, severe pulmonary disease, and 
meningitis/meningoencephalitis consists of three phases: 
induction, consolidation, and maintenance. A combi-
nation of two drugs is preferred in the induction phase. 
Fluconazole monotherapy is recommended during con-
solidation and maintenance phases (Table 1) [2].
Amphotericin B plus flucytosine has been shown to be 
the most potent and advocated regimen for the induction 
phase [2, 9, 73–77]. Intravenous amphotericin B deoxy-
cholate should be given at a dose of 0.7–1 mg/kg/day [2, 
9]. Liposomal amphotericin B at a dose of 3–4 mg/kg/day 
or amphotericin B lipid complex at a dose of 5  mg/kg/
day can be used as a substitute for amphotericin B deoxy-
cholate, as these formulations cause less nephrotoxic-
ity and infusion reaction, while demonstrating similar, if 
not better, efficacy [78, 79]. Flucytosine should be used 
at a dose of 100 mg/kg/day, given in four divided doses. 
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Alternative regimens for the induction phase include 
amphotericin B plus fluconazole, amphotericin B mono-
therapy, fluconazole plus flucytosine, and high-dose flu-
conazole monotherapy [2, 9]. Unfortunately, flucytosine 
is not available in many countries in resource-limited set-
tings and cannot be used in patients with bone marrow 
suppression and liver enzyme elevations. Amphotericin B 
deoxycholate at a dose of 0.7 mg/kg/day plus 800 mg/day 
of fluconazole might have better efficacy than ampho-
tericin B alone [73, 79–81]. A high fluconazole dosage 
at 800  mg/day is also associated with high serum and 
CSF fluconazole concentration and appears to be associ-
ated with increased survival and treatment success [82]. 
Moreover, no additional toxicity was observed [73, 79–
81]. If the patient cannot tolerate amphotericin B or the 
drug is not available, the induction phase can be achieved 
by fluconazole plus flucytosine, or high-dose fluconazole 
monotherapy (Table  1) [2, 9]. However, these two regi-
mens have lowered efficacy. As a result, higher doses of 
fluconazole and longer durations of treatment are sug-
gested [2, 9, 83]. Fluconazole plus flucytosine has proven 
better than fluconazole monotherapy [84–86].
After the Induction phase of treatment, the consolida-
tion phase commences. Longer durations of induction 
should be considered if clinical improvement is not evi-
dent and/or CSF culture at 2 weeks is still positive [2, 9]. 
Patients who fail to achieve negative CSF culture after 
2  weeks were shown to have higher risks for treatment 
failure at 10 weeks [87]. Fluconazole is the drug of choice 
during this phase (Table 1). It is noted that 800 mg/day, 
rather than 400 mg/day, of fluconazole should be used if 
amphotericin B plus fluconazole regimen is selected for 
induction. The consolidation phase continues for at least 
8 weeks. Then, the fluconazole dose should be reduced to 
200 mg/day during the maintenance phase. As long as the 
patients’ CD4 cell counts remain low, they are still at high 
risk for relapse. The maintenance phase can be safely dis-
continued in patients who have been treated for at least 
12  months, have suppressed or very low viral load, and 
have CD4 counts >100  cells/µL for at least 3  months 
[88–92].
Other azoles, such as itraconazole, voriconazole, posa-
conazole, and isavuconazole, also possess anti-crypto-
coccal activity. However, given the scarcity of studies of 
clinical efficacy, potential drug interactions, CNS pen-
etration, and bioavailability, they are reserved for refrac-
tory cases only [2, 9, 75, 93–99].
Resistance to antifungal drugs was previously rare. 
However, recent reports described increased MICs of C. 
neoformans isolates to fluconazole and, to a lesser extent, 
amphotericin B over the past decade [100, 101]. Whether 
this has an impact on clinical outcomes is not known. 
Furthermore, clinical breakpoints of Cryptococcus spp. 
to antifungal drugs are not yet established. Some small 
studies suggested that worse treatment outcomes might 
be associated with higher MICs to antifungal drugs, 
although this is still controversial [100–105]. Currently, 
testing for antifungal susceptibility might be considered 
only in patients with persistent or relapse disease [2, 9]. 
An MIC of ≥16  µg/mL for fluconazole may be consid-
ered resistant, and alternative treatment is suggested, 
e.g. intravenous amphotericin B deoxycholate at a dose 
of 1  mg/kg/day until CSF, blood, and/or other sites are 
sterile [2]. An MIC of ≥32 µg/mL for flucytosine may be 
considered resistant, and the induction phase with non-
flucytosine-containing regimen may be selected [2].
Cerebral cryptococcoma should be treated with the 
same regimen used for cryptococcal meningitis, but 
with an extended duration of therapy (Table 1) [2]. This 
Table 1 Antifungal therapy for  cryptococcosis in  HIV-
infected patients
a For cerebral cryptococcoma, consider induction treatment for ≥6 weeks 
and consolidation and maintenance treatment for 6–18 months; for 
isolated cryptococcal antigenemia, consider (1) induction treatment with 
oral fluconazole at the dose of 800 mg/day for 2 weeks, then proceed to 
consolidation and maintenance treatment, or (2) oral fluconazole at the dose of 
400 mg/day for 12 months
b Liposomal amphotericin B (3–4 mg/kg/day; as high as 6 mg/kg/day) or 
Amphotericin B lipid complex (5 mg/kg/day) serves as an alternative to 
amphotericin B deoxycholate, with less nephrotoxicity and infusion reaction
c Patients should have suppressed or very low viral load, and have CD4 counts 
>100 cells/μl for at least 3 months before discontinuing maintenance treatment
Meningitis/meningoencephalitis, disseminated disease, severe pulmo-
nary diseasea
 Induction phase




   Amphotericin B deoxycholate (0.7–1 mg/kg/day) plus 
fluconazole (800 mg/day)
2 weeks
   Amphotericin B deoxycholateb (0.7–1 mg/kg/day) 4–6 weeks
   Fluconazole (≥800 mg/day, preferably 1200 mg/day) 
plus flucytosine (100 mg/kg/day)
6 weeks
   Fluconazole (800–2000 mg/day, preferably 
≥1200 mg/day)
10–12 weeks
   Itraconazole (400 mg/day) 10–12 weeks
Consolidation phase
  Fluconazole (400 mg/day) 8 weeks
 Alternative regimens
   Itraconazole (400 mg/day) 8 weeks
Maintenance phase
  Fluconazole (200 mg/day) ≥1 yearc
 Alternative regimens
   Itraconazole (400 mg/day) ≥1 yearc
   Amphotericin B deoxycholate (1 mg/kg/week) ≥1 yearc
Mild-to-moderate pulmonary disease
  Fluconazole (400 mg/day) 6–12 months
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should also be guided by clinical response and imaging 
during treatment. The recommended dose of fluconazole 
during consolidation is 400–800  mg/day [2]. Surgery is 
rarely necessary, except when other etiologies are sus-
pected and histopathological diagnosis is required, or 
mass effect is observed. It is noteworthy that an MRI of 
the brain may not show a decrease in lesion size for many 
months [106]. Adjunctive treatment with corticosteroids 
with gradual tapering might be considered in patients 
with significant perilesional edema [2].
Pulmonary cryptococcosis in HIV-infected patients 
is frequently a manifestation of disseminated disease. 
Hence, these patients should be evaluated for CNS 
involvement and disease dissemination, even if they are 
asymptomatic. A CSF examination, culture, as well as 
testing for cryptococcal antigen in the CSF and serum 
should be performed. Disseminated disease should be 
treated with the same regimen as that of cryptococcal 
meningitis [2, 9]. For isolated pulmonary cryptococcosis, 
treatment varies according to severity. Pulmonary cryp-
tococcosis with severe symptoms and/or diffuse pulmo-
nary infiltrates should be treated with regimens identical 
to those for disseminated disease and meningitis [2, 9]. 
For pulmonary cryptococcosis with mild-to-moderate 
symptoms, a dosage of 6  mg/kg/day of oral fluconazole 
for 12  months is recommended [2, 9]. Surgical removal 
and drainage of pleural effusion caused by Cryptococcus 
are rarely required [107].
Similar to pulmonary cryptococcosis, cryptococcal 
infection of other organs is often a manifestation of dis-
seminated disease, especially in HIV-infected patients. 
These patients should be evaluated for CNS involvement 
and disease dissemination as well [2, 9]. For ocular cryp-
tococcosis, combined antifungal agents using systemic 
amphotericin B with high-eye penetration drugs, such as 
flucytosine or fluconazole, are recommended [2].
Positive serum cryptococcal antigen has been shown 
to be associated with subsequent cryptococcal disease 
[108–110]. Screening for serum cryptococcal antigen in 
asymptomatic HIV-infected patients with CD4 counts 
<100  cells/µL and preemptive treatment of those who 
test positive lead to more favorable outcomes and more 
cost-effectiveness [63–65, 108, 109, 111–113]. Antifungal 
regimens have been proposed [9, 114] although sparse 
data exist: (1) oral fluconazole at the dose of 800 mg/day 
for 2  weeks, followed by 400  mg/day for 8  weeks, and 
200  mg/day thereafter until CD4 count is >200  cells/µL 
[65], or (2) oral fluconazole at the dose of 400 mg/day for 
1  year. HIV-infected patients with serum antigen titer 
≥1:512 may be treated as CNS disease [2].
Pregnant women with cryptococcosis represent a spe-
cial population. Amphotericin B can be used safely with-
out risk of teratogenicity in humans (FDA pregnancy 
category B) [2, 9, 115]. Use of other antifungal agents, 
however, should be considered when the benefits out-
weigh fetal risks. Flucytosine is classified as category C 
by the FDA. Although animal studies showed teratogenic 
effect of flucytosine, limited studies in humans showed 
no adverse fetal outcomes after exposure [112]. Flucona-
zole is classified as category D. There are few reports of 
fetal anomalies in pregnant women who had received 
≥400  mg/day of fluconazole [116]. Use of fluconazole, 
as well as other azoles, is thereby discouraged during 
pregnancy, especially in the first trimester [2, 9, 112]. 
Neonates born to patients receiving amphotericin B at 
delivery should be evaluated for renal function and elec-
trolytes [9].
Intracranial pressure management for cryptococcal 
meningitis
In cryptococcal meningitis, intracranial pressure rises 
along with CSF fungal burden and is associated with 
morbidity and mortality [10–12]. Increased intracranial 
pressure may be more prominent in cerebral cryptococ-
coma. Aggressive control of intracranial pressure should 
be done [2, 9]. Management options include therapeu-
tic lumbar puncture, lumbar drain insertion [117], ven-
triculostomy, or ventriculoperitoneal shunt. Therapeutic 
lumbar puncture is usually selected in most cases. CSF 
opening pressure should be measured before treatment, 
and therapeutic lumbar punctures to achieve closing 
pressure below 20 cm H2O or 50% of initial opening pres-
sure are recommended [2, 9]. Brain imaging before the 
procedure should be considered for patients with altera-
tion of consciousness and/or focal neurological deficits. 
Lumbar puncture should be performed whenever symp-
toms of increased intracranial pressure arise. Persistently 
increased intracranial pressure should be managed by 
daily lumbar puncture until symptoms abate and normal 
opening pressure is obtained for >2 days [2, 9]. Interest-
ingly, a recent study showed far less deaths in patients 
who received at least one therapeutic lumbar puncture, 
compared to those who did not, regardless of baseline 
opening pressure [118]. This finding underscores the 
importance of therapeutic lumbar puncture. Failure to 
control intracranial pressure with lumbar puncture war-
rants the need of lumbar drain insertion, ventriculos-
tomy, or CSF shunt placement. This can be performed 
without a need for CSF sterilization before the procedure 
[2, 9]. Patients who experience increased intracranial 
pressure as a manifestation of IRIS should be managed 
alike.
Medical treatment such as corticosteroids, mannitol, 
and acetazolamide are ineffective and should not be used 
[2, 9]. A recent randomized controlled trial showed that 
routine use of corticosteroids in cryptococcal meningitis 
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might do harm to the patients. This study was terminated 
prematurely, because there was no difference in mortality 
or the rate of IRIS between the two groups at 10 weeks 
[119]. Additionally, the use of steroids was associated 
with higher risks of disability, higher adverse events, and 
reduced sterilizing power of amphotericin B plus flu-
conazole during the induction phase. Therefore, its use 
is limited to patients with CNS IRIS and cerebral cryp-
tococcoma with significant edema [2, 9]. Table 2 summa-
rizes intracranial pressure management for cryptococcal 
meningitis.
Treatment monitoring and treatment failure 
of cryptococcosis
After appropriate treatment, clinical improvement 
should be observed, usually within 2  weeks. In patients 
with cryptococcal meningitis, increased intracranial 
pressure usually resolves. Follow-up CSF cultures gradu-
ally turn negative. It is recommended by several experts 
that a CSF culture at 2 weeks should be sent to determine 
CSF sterility after induction phase [2, 9]. A persistently 
positive CSF culture at 2 weeks after treatment is associ-
ated with morbidity and mortality, higher risk for treat-
ment failure at 10  weeks, relapse, and paradoxical IRIS 
[76, 87, 120–123]. Serial CSF quantitative cultures have 
been used as a determinant of fungicidal activity of given 
treatment regimens, and have been shown to be corre-
lated with morbidity and mortality [9, 73, 75–77, 84, 124]. 
However, a quantitative culture is rarely done merely for 
clinical purposes.
Management of patients who fail to achieve CSF ste-
rility at 2  weeks awaits more data, but experts suggest 
induction therapy for another 2  weeks and a follow-up 
CSF culture obtained [2, 9]. Nonetheless, the CSF cul-
tures in some of these patients appear to become negative 
later with continued consolidation therapy [77, 121, 122, 
125]. Of note, despite a good correlation between quanti-
tative CSF cultures and cryptococcal antigens at baseline, 
their kinetics of clearance after treatment differ [126]. 
CSF cryptococcal antigens may persist for an extended 
period even if the culture is negative. Using cryptococcal 
antigen titer to make decisions during therapy is of lim-
ited value and is not advisable [2, 9, 127, 128]. Likewise, 
continued presence of yeasts visualized by India ink does 
not indicate treatment failure or disease relapse.
Persistence is arbitrarily defined as lack of clini-
cal improvement and continued positive cultures after 
2–4 weeks of appropriate therapy [2, 9]. In such a case, 
it should be assessed whether the treatment regimen, 
intracranial pressure management, as well as treat-
ment adherence are optimal. Potential drug interaction 
should be sought. Brain imaging might be considered 
to rule out cryptococcoma. Although rare, concomitant 
opportunistic infections or malignancy is also possible, 
given the usually severe immunocompromised status of 
the patients [129] and proper investigations should be 
sent. In addition, MICs of the persistent isolate should 
be checked and compared with those of the original iso-
late [2, 9]. A ≥3-dilution increase suggests development 
of drug resistance [2]. Re-induction, typically with com-
bined antifungal agents, should be administered. A stand-
ard regimen should be used if a regimen with lowered 
efficacy was previously given. Higher dose and/or longer 
course (4–10 weeks) may be considered [2, 9]. Although 
more clinical studies are required, MICs may be used to 
guide treatment regimen selection, as mentioned above. 
There are few case reports that describe a successful out-
come of a combination of multiple antifungal agents, 
including newer azoles, or adjunctive treatment with 
recombinant interferon-γ1b [95, 128, 130, 131].
Relapse is defined as a recurrence of symptoms, after 
an initial resolution, with a positive CSF culture after 
≥4 weeks of treatment [2, 9]. It remains challenging for 
clinicians taking care of patients who develop recur-
rent symptoms, as this may be secondary to several 
possible etiologies. These include disease relapse, para-
doxical IRIS, new opportunistic conditions, drug toxicity, 
Table 2 Intracranial pressure management for  cryptococ-
cal meningitis in HIV-infected patients
a Brain imaging before the procedure should be considered for patients with 
alteration of consciousness and/or focal neurological deficits. Lumbar puncture 
should be performed whenever symptoms of increased intracranial pressure 
arise. Persistently increased intracranial pressure should be managed by 
daily lumbar puncture until symptoms abate and normal opening pressure is 
obtained for >2 days
b Therapeutic lumbar punctures to achieve closing pressure below 20 cm H2O 
or 50% of initial opening pressure are recommended
c Can be performed without a need for CSF sterilization before the procedure
d The use of steroids was associated with higher risks of disability, higher 
adverse events, and reduced sterilizing power of amphotericin B plus 
fluconazole during the induction phase
Meningitis/meningoencephalitis
 Aggressive control of intracranial pressurea
 Management options
  Therapeutic lumbar punctureb (usually selected in most cases)
  Lumbar drain insertion
  Ventriculostomy
  Ventriculoperitoneal shuntc
 Medical treatment i.e. corticosteroidd, mannitol, and acetazolamide are 
ineffective
Cryptococcoma
 Management as in meningitis/meningoencephalitis
 Corticosteroids may be used in cryptococcoma with significant brain 
edema
Cryptococcal IRIS
 Management as in meningitis/meningoencephalitis
 Corticosteroids may be used in severe IRIS
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or a combination thereof. It is crucial to determine the 
etiology, as each requires a distinct management strat-
egy. However, it is difficult to distinguish by clinical signs 
and symptoms of the patients alone. Thus, further inves-
tigations both for Cryptococcus spp. and other poten-
tial pathogens are warranted. Disease relapse may be 
more likely if the patient has not yet received ART or 
has virologic failure. Patients who received inadequate 
induction treatment and/or had poor adherence to con-
solidation/maintenance therapy are also at high risk for 
disease relapse. Relapse was more frequent in cohorts 
using induction therapy with only fluconazole mono-
therapy [45, 88]. Among patients without these clues, 
discriminating between disease relapse and IRIS is dif-
ficult. Limited data showed that patients with disease 
relapse returned later, were less likely to receive ART, had 
less CD4 count increases and less viral load declines in 
response to ART, and had lower CSF opening pressure 
than those with IRIS [132]. Another recent study stated 
that no clinical features differentiated relapse from IRIS, 
but demonstrated lower CSF WBC counts and lower 
CSF interferon-γ, TNF-α, IL-4, IL-9, IL-12, and IL-17 
[52]. Yet another study showed that serum CRP levels 
were all normal in patients with disease relapse, while 
those of patients with IRIS were elevated in 76% [44]. 
After all, a CSF culture remains the gold standard for 
diagnosing disease relapse [2]. Of note, antifungal treat-
ment might delay the yeast growth, and it may take up to 
4 weeks to obtain the final result. In practice, induction 
therapy should be reinstituted, while CSF culture result is 
pending. If the disease relapse is confirmed, experts rec-
ommend management similar to that of persistent—re-
induction, probably with a higher dose and longer course, 
and selecting the regimen according to MICs of the yeast 
[2]. Newer azoles may be considered. If the isolate is flu-
conazole-susceptible and poor-adherence is a problem, 
prior suppressive doses of fluconazole may be used [2]. 
Like newly diagnosed patients, those with persistence 
or relapse should be monitored for potential drug toxic-
ity and appropriate intracranial pressure management 
should be exercised.
ART in HIV‑infected patients with cryptococcosis
ART constitutes an essential component in the manage-
ment of AIDS-related cryptococcosis. Most patients 
are antiretroviral-naïve at the time of diagnosis of cryp-
tococcosis. Delayed ART initiation places the patients 
at risk for other opportunistic infections. However, too 
early ART initiation increases the risk of developing 
IRIS. Consequently, the time as to when ART should be 
commenced is crucial. Delayed initiation of ART until at 
least after completion of induction therapy and possibly 
until after completion of consolidation therapy, has been 
recommended [2]. A recent landmark randomized clini-
cal trial conducted in Africa demonstrated that 26-week 
mortality was significantly higher in patients who received 
early ART (1–2  weeks after antifungal treatment) com-
pared with those who received delayed ART (5  weeks 
after antifungal treatment). There was no significant dif-
ference of cryptococcal IRIS between the two groups, 
although it was proposed that early unrecognized CNS 
IRIS might account for the mortality difference [5, 133]. 
For patients with asymptomatic cryptococcal antigene-
mia, optimal timing of ART initiation has not been estab-
lished. Currently, deferred initiation of ART until 5 weeks 
of antifungal therapy in this population is also suggested.
In general, any effective ART regimen is acceptable. 
There is no data regarding the benefit of one certain ART 
regimen over another. Amphotericin B does not affect 
the CYP450 enzyme system; therefore, pharmacokinetic 
interactions between amphotericin B and most antiretro-
viral agents are not expected [134]. However, at the time 
of ART initiation in HIV-infected patients with crypto-
coccosis, antifungal therapy is in the consolidation phase 
with fluconazole. When choosing an initial ART regi-
men, one must consider drug–drug interaction between 
fluconazole and antiretroviral agents. With protease 
inhibitors (PIs), fluconazole may potentially increase PI 
concentrations, primarily due to CYP3A4 inhibition. 
However, these effects do not appear to be clinically sig-
nificant and fluconazole may be coadministered without 
dose adjustment [134].
As a relatively modest inhibitor of CYP3A4, fluconazole 
has the potential to increase concentrations of NNRTIs. 
No significant interactions have been observed with efa-
virenz [134]. A clinical trial of ART initiation in advanced 
HIV-infected patients with cryptococcal meningitis has 
shown that an efavirenz-based regimen is effective, safe, 
and well-tolerated [135]. Concomitant use of flucona-
zole and nevirapine has the most potential clinical rel-
evance. A cohort study to compare the adverse events 
after the initiation of a nevirapine-based regimen in 686 
HIV-infected patients who received and did not receive 
fluconazole has shown that there were no significant dif-
ferences of clinical hepatitis, elevated aminotransferase, 
or skin rashes between groups [136]. In another retro-
spective study of 122 HIV-infected patients who received 
nevirapine, those also taking fluconazole 200 or 400 mg/
day had nevirapine Cmin 76% higher, compared to those 
not taking fluconazole. One patient on fluconazole devel-
oped clinical hepatitis. There was no difference in terms 
of 36-week antiretroviral efficacy between the two groups 
[137]. Nevirapine and fluconazole should be concomi-
tantly used with caution, and patients monitored closely 
for nevirapine-associated adverse events, including hepa-
totoxicity. For rilpivirine, there is no clinical significance 
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of drug interaction with fluconazole [133]. Although 
potential drug interactions between antiretroviral agents 
and amphotericin B, flucytosine, and fluconazole are 
minimal, care must be exercised if other azoles are used. 
Table  3 summarizes ART in HIV-infected patients with 
cryptococcosis.
Overlapping toxicities of antifungal and antiretroviral 
drugs
Amphotericin B has multiple adverse effects, e.g. nephro-
toxicity, anemia, electrolyte abnormalities, and infusion 
reactions [138]. Therefore, careful monitoring of renal 
function, electrolytes, and complete blood counts should 
be done. In sub-Saharan Africa, standardized electro-
lyte supplementation and fluid management for patients 
treated with amphotericin B deoxycholate have been 
associated with improved early survival [139]. Liposomal 
amphotericin B or amphotericin B lipid complex may be 
considered in patients with high risks for drug toxicity. 
Moreover, modification of an amphotericin B deoxycho-
late infusion regimen to 24 h-continuous infusion might 
lower nephrotoxicity without affecting fungicidal activity, 
although data is limited [140, 141].
Regarding overlapping toxicity with antiretroviral 
drugs, both amphotericin B and tenofovir can cause 
nephrotoxicity. Concomitant use of these agents should 
be considered with caution. In a cohort study of 222 HIV-
infected patients, prior exposure to amphotericin B was 
found to be a risk factor for nephrotoxicity [142]. In con-
trast, a recent study showed that tenofovir use in patients 
receiving induction treatment of cryptococcal menin-
gitis with amphotericin B was not associated with short 
term nephrotoxicity, as measured by serum creatinine at 
4  weeks [143]. Nevertheless, close monitoring of serum 
creatinine and urinalysis is recommended for concomi-
tant or sequential use of amphotericin B and tenofovir. If 
renal function is compromised, tenofovir dose should be 
adjusted accordingly.
Anemia represents a common toxicity with ampho-
tericin B therapy in HIV-infected patients with crypto-
coccal meningitis. A recent study has demonstrated that 
amphotericin B-induced anemia was mostly transient 
and did not impact mortality [144]. Amphotericin B may 
also cause anemia when used with zidovudine, due to 
additive bone marrow suppression [133]. Close monitor-
ing of the complete blood count is recommended during 
therapy. Flucytosine use is associated with bone marrow 
suppression and liver toxicity. Adjustment of flucytosine 
dose according to creatinine clearance is essential.
Fluconazole may cause prolongation of the QT inter-
val either directly or by inhibiting the hepatic metabolism 
of other QT-prolonging agents. A clinical trial to assess 
QT intervals in 141 HIV-infected patients with crypto-
coccal meningitis has demonstrated that there were no 
differences of QTc interval prolongation between those 
that received and did not receive fluconazole 800 mg/day 
in addition to amphotericin B in the induction phase of 
treatment [145]. However, high trough concentration of 
fluconazole appears to be associated with a trend towards 
increased risk of QTc prolongation at day 7. Therefore, 
electrocardiogram monitoring of patients taking high-
dose fluconazole should be performed and physicians 
should be aware of other potential risk factors for QTc 
prolongation, particularly hypokalemia.
Immune reconstitution inflammatory syndrome (IRIS)
Immune reconstitution inflammatory syndrome (IRIS) 
is characterized by clinical deterioration with symptoms 
and signs of inflammation, resulting from exaggerated 
host immune responses against pathogens or antigens 
during immune reconstitution. IRIS can occur after ART 
initiation, re-initiation, or switching to a more active reg-
imen following virological failure. It has a wide range of 
clinical manifestations as well as severity. IRIS symptoms 
often mimic those of infections, and represent a diagnos-
tic challenge for clinicians.
IRIS can be classified into paradoxical IRIS and 
unmasking IRIS. The former describes a worsening, after 
an initial clinical improvement of a pre-existing infec-
tious process following ART initiation, while the latter 
describes a subclinical disease that becomes clinically 
apparent after ART introduction. Consensus definitions 
of cryptococcal IRIS have been proposed by the Inter-
national Network for the Study of HIV-associated IRIS 
(INSHI) [146].
Paradoxical cryptococcal IRIS has been reported in 
8–49% of patients with known cryptococcosis at ART 
Table 3 ART in HIV-infected patients with cryptococcosis
a HIV-infected patients who received nevirapine, those also taking fluconazole 
200 or 400 mg/day had nevirapine Cmin 76% higher, compared to those not 
taking fluconazole
Time to start ART
 Deferred until 5 weeks after the start of antifungal therapy
ART regimen
 Consider drug–drug interactions between fluconazole and antiretroviral 
agents
  Fluconazole may potentially increase PI concentrations, but no clinical 
significance
  Fluconazole has the potential to increase NNRTI concentration
   No significant interactions with efavirenz
   Nevirapine has the most potential clinical relevancea
   No significant interactions with rilpivirine
 Monitor closely for nevirapine-associated adverse events, including 
hepatotoxicity
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initiation [146]. The reported manifestations vary from 
relapsing aseptic meningitis, increased intracranial pres-
sure, intracranial cryptococcomas/abscess, spinal cord 
abscess, focal neurological deficits, lymphadenopathy, 
pneumonia, soft-tissue disease, eye disease, fever, and a 
multifocal disease [146–149]. It is noteworthy that IRIS 
can present in organs that were not initially identified 
as infected. The reported onset after ART initiation also 
varies widely, from 4 days to 3 years. The median onsets 
of IRIS after ART initiation from prospective cohorts are 
within 10  weeks [146–149]. In CNS IRIS, a CT scan or 
MRI of the brain may reveal leptomeningeal or choroid 
plexus gadolinium enhancement, diffuse edema, linear 
perivascular enhancement in the sulci, or communicating 
hydrocephalus. This is unlike that of ART-naïve crypto-
coccal meningitis, which often shows minimal inflamma-
tion [56, 150–152]. Meningoradiculitis, enhancing 
cortical lesions in the cortex compatible with cryptococ-
comas, and enhancement of the Virchow-Robin spaces 
can also be seen [56, 150–152].
Pathogenesis of IRIS remains to be further elucidated 
and is currently an active area of research [153–155]. A 
number of investigators compared clinical characteristics 
as well as laboratory results of patients who did and did 
not later develop IRIS, in order to establish risk factors. 
The reported risk factors include low baseline CD4 cell 
counts, high baseline viral load, early ART initiation after 
antifungal therapy, a poor baseline CSF inflammation (as 
judged by low CSF protein and WBC counts), different 
baseline levels of certain CSF cytokines, high baseline 
certain serum cytokines, high fungal burden, CSF culture 
positivity at 2 weeks or at ART initiation, substantial CD4 
count increase after ART, and rapid viral load decrease 
after ART [46, 122, 155–160]. However, these stud-
ies yielded conflicting results, and some factors require 
sophisticated instruments. Such factors might help in the 
prediction, but could not be used as diagnostic criteria. 
Currently, the proposed INSHI criteria serve to guide the 
diagnosis of IRIS [146].
Cryptococcal paradoxical IRIS is a diagnosis of exclu-
sion. Patients with clinical deterioration should be initially 
managed similarly to those with suspected relapse dis-
ease, since other possible etiologies of clinical deteriora-
tion require distinct management as mentioned above. 
Shelburne et  al. showed that patients with paradoxical 
IRIS returned later, were more likely to receive ART, had 
more CD4 count increases and more viral load declines 
in response to ART, and had higher CSF opening pressure 
than those with relapse disease [131]. Higher CSF WBC 
counts and certain CSF cytokines, as well as higher serum 
CRP were observed in other studies [44, 52]. Of note, the 
guideline recommends testing for viral load, but does 
not strictly require it to make the diagnosis. It is deemed 
that current ART regimens typically have excellent viro-
logical response if the patient has good ART adherence 
[146]. CD4 cell count is also not included in the INSHI 
criteria [146]. This is due to the fact that paradoxical IRIS 
was reported in patients with minimally increased CD4 
counts after ART initiation [52].
Management of paradoxical cryptococcal IRIS is based 
on data from case reports and expert opinions. ART 
and antifungal agent(s) continuation are generally rec-
ommended [2, 9]. For mild symptoms, expectant man-
agement is reasonable. For severe symptoms of IRIS, 
corticosteroids [149, 161, 162], NSAIDs [163], and other 
immunomodulating agents, e.g. hydroxychloroquine 
[164], thalidomide [165] and adalimumab [166] have 
been used successfully. CNS IRIS with increased intrac-
ranial pressure might be treated with corticosteroids at 
0.5–1.0  mg/kg/day of prednisone equivalent or higher 
for severe CNS signs and symptoms, followed by a sub-
sequent tapering dose in 2–6  weeks [2]. Durations may 
be adjusted on a case-by-case basis. Aggressive control of 
intracranial pressure is also critical.
In the unmasking IRIS, the symptoms arise after ART 
initiation [167, 168]. Given the difficulty of differentiat-
ing IRIS from progression of untreated subclinical infec-
tion, the term “ART-associated cryptococcosis” was 
coined by the consensus definition to include both pro-
cesses [146]. It occurred in 0.2–1.6% of patients without 
evidence of cryptococcosis before starting ART [146]. 
Much higher incidences have been observed in patients 
with subclinical cryptococcal antigenemia who did not 
receive antifungal therapy [146]. Like paradoxical IRIS, it 
can manifest as meningitis, CNS complications, skin and 
soft-tissue disease, lymphadenitis, lung disease, and a dis-
seminated disease [146]. The reported onset of symptoms 
span a few days to several months. Severe illness usually 
develops over a few days after onset [146]. The proposed 
INSHI definitions are currently used. Management of 
this group of patients should not differ from newly diag-
nosed cryptococcosis in HIV-infected patients without 
ART [153].
Conclusions
The mortality in HIV-infected patients with cryptococ-
cosis is high during the first few months of treatment. 
Managing the two diseases more effectively during this 
critical period is essential to improve the patients’ sur-
vival and quality of life. The time to start ART in HIV-
infected patients with cryptococcosis has to be deferred 
until 5  weeks after the start of antifungal therapy. Inte-
grated therapy of HIV and cryptococcosis including anti-
fungal therapy, intracranial pressure management for 
cryptococcal meningitis, and ART to restore immune 
function is the key to success. Integration of care for both 
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cryptococcosis and HIV using a single facility and a sin-
gle health care provider is a model to deliver integrated 
therapy for both diseases and manage overlapping toxici-
ties of antifungal and antiretroviral drugs and IRIS more 
effectively.
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